Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on HC-FIA

The COVID-19 pandemic has highlighted the need for rapid and accurate nucleic acid detection at the point of care.

11 Dec 2020

Study reveals new target to make breast cancer more sensitive to immunotherapy

Although immunotherapy has been effective in treating different kinds of cancer, it is still unsuccessful when it comes to treating breast cancers.

11 Dec 2020

Genetic modification in the ‘coat’ of fatal brain virus may allow it to escape antibodies

A genetic modification in the 'coat' of a brain infection-causing virus may allow it to escape antibodies, according to Penn State College of Medicine researchers.

23 Nov 2020

Mutations in SARS-CoV-2 spike protein may improve monoclonal antibody resistance

A recent paper examines a mutation of the spike protein of SARS-CoV-2 that has been observed to have arisen independently twice.

10 Nov 2020

Researchers map molecular structure of CV30 antibody to neutralize coronavirus

Scientists at Fred Hutchinson Cancer Research Center in Seattle have shown that a potent antibody from a COVID-19 survivor interferes with a key feature on the surface of the coronavirus's distinctive spikes and induces critical pieces of those spikes to break off in the process.

28 Oct 2020

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

9 Oct 2020

Researchers identify an effective treatment for severe cases of COVID-19 infection

Scientists are trying to figure out how SARS-CoV-2 leads to a range of symptoms that appear to persist long after the active viral infection.

From Osaka University 1 Sep 2020

Researchers discover antibodies that may provide effective immunity against SARS-CoV-2

A new study by researchers at MassBiologics of UMass Medical School published in Nature Communications suggests that COVID specific IgA monoclonal antibodies may provide effective immunity in the respiratory system against the novel coronavirus - a potentially critical feature of an effective vaccine.

25 Aug 2020

A genetic link discovered to predict treatment response for patients with rare, aggressive cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

NIH clinical study to evaluate potential new therapeutics for mild, moderate COVID-19

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

5 Aug 2020

A simple screening process may improve mAb-based drug development

By screening potential monoclonal antibody (mAb)-based drugs solely based on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.

3 Aug 2020

Rapid drug development yields potential treatment for yellow fever

Yellow fever, a hemorrhagic disease that is common in South America and sub-Saharan Africa, infects about 200,000 people per year and causes an estimated 30,000 deaths.

From Massachusetts Institute of Technology (MIT) 30 Jul 2020

NIH establishes clinical trial network to test vaccines and monoclonal antibodies for COVID-19

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trial network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.

14 Jul 2020

Scientists discover role of surface diffusion in protein transport

Many of the most promising medicines under development are proteins, often antibodies, to help patients fight disease. These proteins must be purified as part of the manufacturing process -- a task that can be tricky and result in costly waste.

8 Jul 2020

NJIT researchers develop new efficient method to quantify therapeutic proteins

Researchers at New Jersey Institute of Technology in collaboration with Ohio University and Merck & Co. Inc. recently developed a new efficient method for targeted protein analysis -- one they say could speed up processes for disease testing, drug discovery and vaccine development.

18 Jun 2020

Researchers identify antibody cocktail with potential to neutralize SARS-CoV-2 virus

Researchers at the University of Maryland School of Medicine evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

17 Jun 2020

Cross-neutralization of SARS and COVID-19 coronaviruses by an antibody

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the cause of COVID-19.

19 May 2020

Study shows coronavirus does not induce cross-protective immune antibodies

According to researchers, patients infected with severe acute respiratory syndrome coronavirus (SARS-CoV) or SARS-CoV-2 generate antibodies that adhere to the other coronavirus; however, the cross-reactive antibodies are not actually cross-protective, as far as cell-culture experiments are concerned.

19 May 2020

Discovery Of Antibody That Blocks Infection Of SARS-Cov-2

Researchers reported that they have identified a fully human monoclonal antibody that prevents the SARS-CoV-2 (COVID-19) virus from infecting cultured cells.

4 May 2020

Beta Cells From Stem Cells

The loss of insulin-secreting beta cells leads to type 1 diabetes. Islet cell transplantation has the potential to cure diabetes, but donors are rare.

28 Apr 2020